As the European Union confronts rising infections, the European Union's pharmaceuticals authority suggested on Wednesday that a booster dosage of Johnson & Johnson's COVID-19 injection be given at least two months after the initial treatment in persons aged 18 and older.

The Omicron coronavirus variation is rapidly spreading over the world, with many new cases being connected to it. The World Health Organization has warned that Omicron offers a "very high" danger, although data on its severity is scarce.

The European Medicines Agency (EMA) stated that their decision to authorize J&J booster dosages was based on evidence showing that the extra shot resulted in an increase in antibodies against the COVID-causing SARS-CoV-2 coronavirus.

In accordance with the EMA's guidance on vaccine mixing, a J&J booster dosage may be given after two doses of one of Pfizer-or BioNTech's Moderna's mRNA vaccines.Johnson & Johnson's Covid setback risks damaging its vaccine programme | Financial Times

After at least one patient died in the United Kingdom after contracting the Omicron variety, which was initially found last month in southern Africa and Hong Kong, other EU countries are strengthening restrictions.

The distribution of booster doses is being accelerated because the longevity of protection provided by conventional immunization has been questioned in the wake of Omicron's large number of mutations, which may allow it to evade vaccine protection.

Pfizer-BioNTech and Moderna vaccines have already been approved by the EU authorities as a third booster dosage at least six months following a conventional two-shot course. Booster doses from AstraZeneca are also being considered.